BAKER BROS. ADVISORS LP Q2 2018 Filing
Filed August 14, 2018
Portfolio Value
$13.3B
Holdings
119
Report Date
Q2 2018
Filing Type
13F-HR
All Holdings (119 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | SGENEURSeattle Genetics, Inc. | 51,046,060 | $3.4T | 25463.96% | |
| 2 | INCYIncyte Corporation | 34,251,034 | $2.3T | 17242.87% | |
| 3 | ONCBeiGene, Ltd. | 11,959,824 | $1.8T | 13814.80% | |
| 4 | ALXNAlexion Pharmaceuticals, Inc. | 8,555,894 | $1.1T | 7981.29% | |
| 5 | BMRNBioMarin Pharmaceutical Inc. | 7,583,084 | $714.3B | 5367.33% | |
| 6 | —Genomic Health, Inc. | 13,790,574 | $695.0B | 5222.45% | |
| 7 | ACADACADIA Pharmaceuticals Inc. | 27,228,338 | $415.8B | 3124.08% | |
| 8 | MDGLMadrigal Pharmaceuticals, Inc. | 1,169,278 | $327.0B | 2457.28% | |
| 9 | HRTXHeron Therapeutics, Inc. | 5,025,298 | $195.2B | 1466.95% | |
| 10 | ASNDAscendis Pharma A/S | 2,837,352 | $188.7B | 1418.17% | |
| 11 | MRTXEURMirati Therapeutics, Inc. | 2,513,462 | $123.9B | 931.07% | |
| 12 | —Spark Therapeutics, Inc. | 1,384,130 | $114.6B | 860.72% | |
| 13 | —DBV Technologies S.A. | 5,509,560 | $106.3B | 798.56% | |
| 14 | SG7Sage Therapeutics, Inc. | 613,300 | $96.0B | 721.33% | |
| 15 | ARRYEURArray BioPharma Inc. | 5,656,196 | $94.9B | 713.14% | |
| 16 | NBIXNeurocrine Biosciences, Inc. | 944,624 | $92.8B | 697.28% | |
| 17 | RYTMRhythm Pharmaceuticals, Inc. | 2,708,200 | $84.7B | 636.11% | |
| 18 | BCRXBioCryst Pharmaceuticals, Inc. | 14,012,172 | $80.3B | 603.28% | |
| 19 | ARGXargenx SE | 961,754 | $79.7B | 598.78% | |
| 20 | CERSCerus Corporation | 10,749,937 | $71.7B | 538.76% | |
| 21 | AMRNAmarin Corporation plc | 22,669,509 | $70.0B | 526.34% | |
| 22 | CBAYUSDCymaBay Therapeutics, Inc. | 4,917,700 | $66.0B | 495.88% | |
| 23 | NVTA1EURInvitae Corporation | 8,399,411 | $61.7B | 463.87% | |
| 24 | KNSAKiniksa Pharmaceuticals, Ltd. | 3,000,000 | $52.0B | 391.09% | |
| 25 | —Idera Pharmaceuticals, Inc. | 38,654,811 | $51.0B | 383.39% | |
| 26 | 1T7Tricida, Inc. | 1,600,000 | $47.8B | 359.46% | |
| 27 | —GW Pharmaceuticals plc | 321,800 | $44.9B | 337.40% | |
| 28 | NVAX 3.75 02/01/23Novavax, Inc. | 73,500,000 | $42.7B | 320.59% | |
| 29 | —Abeona Therapeutics Inc. | 2,184,364 | $35.0B | 262.61% | |
| 30 | ERYP1EURERYTECH Pharma S.A. | 3,085,969 | $34.5B | 259.00% | |
| 31 | XNCRXencor, Inc. | 872,072 | $32.3B | 242.51% | |
| 32 | —Endocyte, Inc. | 2,277,799 | $31.4B | 236.19% | |
| 33 | —bluebird bio, Inc. | 200,000 | $31.4B | 235.86% | |
| 34 | —Bellicum Pharmaceuticals, Inc. | 4,093,447 | $30.2B | 226.99% | |
| 35 | —Aquinox Pharmaceuticals, Inc. | 10,934,154 | $29.0B | 217.72% | |
| 36 | MRUSMerus N.V. | 1,160,014 | $26.4B | 198.38% | |
| 37 | GLPGGalapagos NV | 259,894 | $24.0B | 180.01% | |
| 38 | QUREuniQure N.V. | 605,000 | $22.9B | 171.83% | |
| 39 | HALOHalozyme Therapeutics, Inc. | 1,283,929 | $21.7B | 162.75% | |
| 40 | —MyoKardia, Inc. | 433,121 | $21.5B | 161.58% | |
| 41 | SLDBSolid Biosciences Inc. | 587,884 | $20.9B | 157.38% | |
| 42 | —Zymeworks Inc. | 1,311,085 | $19.4B | 145.60% | |
| 43 | GBYSangamo Therapeutics, Inc. | 1,283,923 | $18.2B | 136.99% | |
| 44 | —Aimmune Therapeutics, Inc. | 673,908 | $18.1B | 136.16% | |
| 45 | IM8NInsmed Incorporated | 700,000 | $16.6B | 124.39% | |
| 46 | —ContraFect Corporation | 7,153,076 | $15.8B | 118.78% | |
| 47 | —Clementia Pharmaceuticals Inc. | 1,192,595 | $15.7B | 117.93% | |
| 48 | BMRN 0.599 08/01/24BioMarin Pharmaceutical Inc. | 15,000,000 | $15.2B | 114.20% | |
| 49 | —Audentes Therapeutics, Inc. | 393,222 | $15.0B | 112.90% | |
| 50 | NTLAIntellia Therapeutics, Inc. | 546,922 | $15.0B | 112.44% | |
| 51 | AGLEUSDAeglea BioTherapeutics, Inc. | 1,387,872 | $14.7B | 110.33% | |
| 52 | NBIX 2.25 05/15/24Neurocrine Biosciences, Inc. | 10,000,000 | $14.5B | 108.69% | |
| 53 | —BioMarin Pharmaceutical Inc. | 12,228,000 | $13.0B | 97.68% | |
| 54 | CPRXCatalyst Pharmaceuticals, Inc. | 3,621,962 | $11.3B | 84.91% | |
| 55 | EX9Exelixis, Inc. | 513,410 | $11.0B | 83.02% | |
| 56 | —Corsicanto II Designated Activity Company | 10,000,000 | $10.9B | 81.96% | |
| 57 | BDQMAlbireo Pharma, Inc. | 250,000 | $8.9B | 66.69% | |
| 58 | IFRXInflaRx N.V. | 258,824 | $8.3B | 62.72% | |
| 59 | XLRNAcceleron Pharma Inc. | 163,900 | $8.0B | 59.75% | |
| 60 | —Progenics Pharmaceuticals, Inc. | 979,016 | $7.9B | 59.14% | |
| 61 | GLMDGalmed Pharmaceuticals Ltd. | 636,140 | $7.6B | 56.88% | |
| 62 | —Foamix Pharmaceuticals Ltd. | 1,490,201 | $7.5B | 56.10% | |
| 63 | GTHXEURG1 Therapeutics, Inc. | 169,492 | $7.4B | 55.35% | |
| 64 | —Momenta Pharmaceuticals, Inc. | 308,500 | $6.3B | 47.40% | |
| 65 | AUTLAutolus Therapeutics plc | 235,294 | $6.3B | 47.37% | |
| 66 | —Aegerion Pharmaceuticals, Inc. | 9,517,000 | $6.0B | 45.29% | |
| 67 | VNDAVanda Pharmaceuticals Inc. | 310,354 | $5.9B | 44.42% | |
| 68 | —Syros Pharmaceuticals, Inc. | 574,835 | $5.9B | 44.10% | |
| 69 | ASMBAssembly Biosciences, Inc. | 148,587 | $5.8B | 43.78% | |
| 70 | —Menlo Therapeutics Inc. | 700,000 | $5.7B | 42.71% | |
| 71 | —Achillion Pharmaceuticals, Inc. | 1,943,620 | $5.5B | 41.33% | |
| 72 | CCXIEURChemoCentryx, Inc. | 414,029 | $5.5B | 40.97% | |
| 73 | ANABAnaptysBio, Inc. | 73,086 | $5.2B | 39.01% | |
| 74 | —Sesen Bio, Inc. | 2,624,412 | $5.1B | 38.46% | |
| 75 | —Acorda Therapeutics, Inc. | 173,100 | $5.0B | 37.33% | |
| 76 | —Versartis, Inc. | 2,426,310 | $4.9B | 36.92% | |
| 77 | GLYCEURGlycoMimetics, Inc. | 291,214 | $4.7B | 35.29% | |
| 78 | —La Jolla Pharmaceutical Company | 154,675 | $4.5B | 33.90% | |
| 79 | —Aevi Genomic Medicine, Inc. | 4,055,142 | $4.5B | 33.82% | |
| 80 | MGNXMacroGenics, Inc. | 217,695 | $4.5B | 33.77% | |
| 81 | —Adamas Pharmaceuticals, Inc. | 172,630 | $4.5B | 33.50% | |
| 82 | —Spring Bank Pharmaceuticals, Inc. | 373,144 | $4.4B | 33.23% | |
| 83 | APLSApellis Pharmaceuticals, Inc. | 196,078 | $4.3B | 32.41% | |
| 84 | NTRANatera, Inc. | 228,676 | $4.3B | 32.34% | |
| 85 | ALKSAlkermes plc | 100,251 | $4.1B | 31.00% | |
| 86 | AERIEURAerie Pharmaceuticals, Inc. | 60,155 | $4.1B | 30.53% | |
| 87 | —Forty Seven, Inc. | 250,000 | $4.0B | 30.06% | |
| 88 | TTPHEURTetraphase Pharmaceuticals, Inc. | 935,000 | $3.3B | 25.08% | |
| 89 | —Nabriva Therapeutics plc | 938,235 | $3.3B | 24.53% | |
| 90 | —Tonix Pharmaceuticals Holdings Corp. | 699,500 | $3.1B | 23.39% | |
| 91 | TREURTrillium Therapeutics Inc. | 511,763 | $3.1B | 23.07% | |
| 92 | KRYSKrystal Biotech, Inc. | 200,000 | $3.0B | 22.35% | |
| 93 | RIGLUSDRigel Pharmaceuticals, Inc. | 1,041,612 | $2.9B | 22.15% | |
| 94 | —NewLink Genetics Corporation | 507,273 | $2.4B | 18.15% | |
| 95 | OVIDOvid Therapeutics Inc. | 247,733 | $1.9B | 14.52% | |
| 96 | —Ra Pharmaceuticals, Inc. | 177,952 | $1.8B | 13.31% | |
| 97 | —MediWound Ltd. | 226,000 | $1.6B | 11.71% | |
| 98 | RCUSArcus Biosciences, Inc. | 121,534 | $1.5B | 11.18% | |
| 99 | CLLSCellectis S.A. | 50,000 | $1.4B | 10.63% | |
| 100 | —Trevena, Inc. | 950,000 | $1.4B | 10.28% |
Page 1 of 2Next